Gastric Functions & Proton Pump Inhibitor( PPI) Study
Status:
Completed
Trial end date:
2016-02-19
Target enrollment:
Participant gender:
Summary
Functional dyspepsia is one of the most common digestive disorders. The pathophysiology of
functional dyspepsia is uncertain. Proton pump inhibitor (PPI) has been recommended as the
first line treatment for functional dyspepsia. However, the mechanism of symptom relief is
unclear. Most of the previous studies were performed on healthy volunteers who received only
a very short course of PPI. The correlation between symptom and gastric emptying is lacking
in these studies.
Demographic data and anthropometric measurements will be obtained for baseline assessment.
Patients are required to complete FGI Screening Questionnaire, Functional dyspepsia symptom
questionnaire, gastroesophageal reflux disease (GERD) symptom questionnaire and irritable
bowel syndrome (IBS) symptom questionnaire to have a thorough assessment of their GI
symptoms. (1) Satiety test and ghrelin profile, and (2)gastric emptying test will be arranged
as two individual visits.
After baseline investigations, patients will be randomly assigned to either Nexium 20 mg
daily or identical looking placebo for 8 weeks. The patients will report their individual
dyspeptic symptoms on weekly basis using a self-administered symptom questionnaire.
Satiety test and ghrelin profile, gastric emptying study will be repeated at the end of
8-week treatment.
Hypothesis: Long-term PPI relieves dyspeptic symptom through acceleration of gastric emptying
rate.